Vormatrigine for Epilepsy

(POWER2 Trial)

This trial tests a new medication, vormatrigine, to determine its effectiveness for people with focal seizures, a type of epilepsy where seizures begin in one part of the brain. The goal is to assess whether vormatrigine is safe and effective compared to a placebo (a pill with no active medicine). Participants will receive one of three different doses of vormatrigine or a placebo for 12 weeks. The trial seeks individuals diagnosed with focal onset epilepsy who experience at least four seizures a month and are on stable medication. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial requires that you continue taking stable doses of 1 to 3 acceptable anti-seizure medications (ASMs) for at least 4 weeks before and during the trial. If you are taking felbamate, you must have been on it for at least 2 years with a stable dose for 2 months before the trial.

Research shows that vormatrigine is generally well-tolerated by people with epilepsy. Earlier studies found vormatrigine to be safe. Most side effects during treatment are mild or moderate. Additionally, new information suggests that vormatrigine can work effectively in the body without causing major side effects. Thus far, vormatrigine appears safe for humans, with no major safety concerns reported.¹²³⁴⁵

Vormatrogine is unique because it offers a potentially novel approach to treating epilepsy. While most treatments for epilepsy, like valproate or carbamazepine, work by stabilizing electrical activity in the brain, vormatrogine may have a different mechanism of action, which could lead to fewer side effects or improved efficacy. Researchers are excited about vormatrogine because of its potential to provide better seizure control and improve the quality of life for patients who may not respond well to existing medications. By exploring multiple dosage levels (20 mg, 30 mg, and 40 mg), the trial aims to determine the most effective dose with the least side effects.

Research has shown that vormatrigine may help treat epilepsy by reducing seizures. One study found that patients experienced an average 56.3% reduction in seizure frequency over eight weeks. Notably, 22% of participants had no seizures during the last four weeks of treatment. These findings suggest that vormatrigine could effectively manage focal seizures. Additionally, vormatrigine is considered safe, making it a potentially appealing choice for patients.¹²³⁴⁶